ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM
Abstract Number: 1611
Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study
Vasculitis – ANCA-Associated Poster II
10:30AM-12:30PM
Abstract Number: 1198
Impact of Metabolic Syndrome on Knee Osteoarthritis Severity and Progression: A PROCOAC Cohort Study
Osteoarthritis – Clinical Poster I
10:30AM-12:30PM
Abstract Number: 1411
Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life
Sjögren's Syndrome – Basic & Clinical Science Poster I
10:30AM-12:30PM
Abstract Number: 1055
Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis
Health Services Research – ACR/ARP Poster II
10:30AM-12:30PM
Abstract Number: 1111
Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Miscellaneous Rheumatic & Inflammatory Diseases Poster II
10:30AM-12:30PM
Abstract Number: 1045
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Health Services Research – ACR/ARP Poster II
10:30AM-12:30PM
Abstract Number: 1522
Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
SLE – Diagnosis, Manifestations, & Outcomes Poster II
10:30AM-12:30PM
Abstract Number: 1047
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Health Services Research – ACR/ARP Poster II
10:30AM-12:30PM
Abstract Number: 1625
Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II
10:30AM-12:30PM
Abstract Number: 1275
Implementing Integrated Mental Health Care in a Juvenile Myositis Clinic: A One-Year Review
Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1168
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 1543
Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
SLE – Treatment Poster II
10:30AM-12:30PM
Abstract Number: 1068
Improving Health Numeracy Literacy in Pediatric Patients with SLE
Measures & Measurement of Healthcare Quality Poster
10:30AM-12:30PM
Abstract Number: 1264
Improving Mental Health Care for Youth with Juvenile Dermatomyositis Through Integration of Mental Health Screening into Pediatric Rheumatology Clinic
Pediatric Rheumatology – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 1021
Improving Preoperative Osteoporosis Screening for Orthopedic Patients
Healthcare Disparities in Rheumatology Poster II
  • «Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 59
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology